speb/financial-data huggingface dataset:
DNA income_statement (annual, 2023-12-31) — Other Gand A: 385025000.00
DNA income_statement (annual, 2023-12-31) — Other Income Expense: -181868000.00
DNA balance_sheet (annual, 2023-12-31) — Other Intangible Assets: 82741000.00
DNA balance_sheet (annual, 2023-12-31) — Other Investments: 23898000.00
DNA cash_flow (annual, 2023-12-31) — Other Non Cash Items: 50900000.00
DNA balance_sheet (annual, 2023-12-31) — Other Non Current Assets: 58055000.00
DNA balance_sheet (annual, 2023-12-31) — Other Non Current Liabilities: 24433000.00
DNA income_statement (annual, 2023-12-31) — Other Non Operating Income Expenses: 9138000.00
DNA balance_sheet (annual, 2023-12-31) — Other Properties: 353986000.00
DNA balance_sheet (annual, 2023-12-31) — Other Receivables: 1546000.00
DNA income_statement (annual, 2023-12-31) — Otherunder Preferred Stock Dividend: 0.00
DNA balance_sheet (annual, 2023-12-31) — Payables: 9323000.00
DNA balance_sheet (annual, 2023-12-31) — Payables And Accrued Expenses: 43510000.00
DNA balance_sheet (annual, 2023-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 15678000.00
DNA balance_sheet (annual, 2023-12-31) — Preferred Stock: 0.00
DNA balance_sheet (annual, 2023-12-31) — Prepaid Assets: 20741000.00
DNA income_statement (annual, 2023-12-31) — Pretax Income: -892940000.00
DNA cash_flow (annual, 2023-12-31) — Proceeds From Stock Option Exercised: 93000.00
DNA balance_sheet (annual, 2023-12-31) — Properties: 0.00
DNA cash_flow (annual, 2023-12-31) — Purchase Of Business: -42980000.00
DNA cash_flow (annual, 2023-12-31) — Purchase Of Investment: 0.00
DNA cash_flow (annual, 2023-12-31) — Purchase Of PPE: -40801000.00
DNA balance_sheet (annual, 2023-12-31) — Receivables: 17899000.00
DNA income_statement (annual, 2023-12-31) — Reconciled Cost Of Revenue: 54005000.00
DNA income_statement (annual, 2023-12-31) — Reconciled Depreciation: 70507000.00
DNA cash_flow (annual, 2023-12-31) — Repayment Of Debt: -1295000.00
DNA cash_flow (annual, 2023-12-31) — Repurchase Of Capital Stock: 0.00
DNA income_statement (annual, 2023-12-31) — Research And Development: 580621000.00
DNA balance_sheet (annual, 2023-12-31) — Restricted Cash: 4789000.00
DNA income_statement (annual, 2023-12-31) — Restructuring And Mergern Acquisition: 0.00
DNA balance_sheet (annual, 2023-12-31) — Retained Earnings: -5290528000.00
DNA cash_flow (annual, 2023-12-31) — Sale Of Investment: 0.00
DNA cash_flow (annual, 2023-12-31) — Sale Of PPE: 4428000.00
DNA income_statement (annual, 2023-12-31) — Selling General And Administration: 385025000.00
DNA balance_sheet (annual, 2023-12-31) — Share Issued: 50032875.00
DNA income_statement (annual, 2023-12-31) — Special Income Charges: -138712000.00
DNA cash_flow (annual, 2023-12-31) — Stock Based Compensation: 229884000.00
DNA balance_sheet (annual, 2023-12-31) — Stockholders Equity: 1097152000.00
DNA balance_sheet (annual, 2023-12-31) — Tangible Book Value: 965173000.00
DNA income_statement (annual, 2023-12-31) — Tax Effect Of Unusual Items: -14977.87
DNA income_statement (annual, 2023-12-31) — Tax Provision: -71000.00
DNA income_statement (annual, 2023-12-31) — Tax Rate For Calcs:
DNA balance_sheet (annual, 2023-12-31) — Total Assets: 1665342000.00
DNA balance_sheet (annual, 2023-12-31) — Total Capitalization: 1097152000.00
DNA balance_sheet (annual, 2023-12-31) — Total Debt: 239309000.00
DNA balance_sheet (annual, 2023-12-31) — Total Equity Gross Minority Interest: 1097152000.00
DNA income_statement (annual, 2023-12-31) — Total Expenses: 1019651000.00
DNA balance_sheet (annual, 2023-12-31) — Total Liabilities Net Minority Interest: 568190000.00
DNA balance_sheet (annual, 2023-12-31) — Total Non Current Assets: 663593000.00
DNA balance_sheet (annual, 2023-12-31) — Total Non Current Liabilities Net Minority Interest: 404330000.00
DNA income_statement (annual, 2023-12-31) — Total Operating Income As Reported: -864406000.00
DNA income_statement (annual, 2023-12-31) — Total Unusual Items: -188371000.00
DNA income_statement (annual, 2023-12-31) — Total Unusual Items Excluding Goodwill: -188371000.00
DNA balance_sheet (annual, 2023-12-31) — Treasury Shares Number: 0.00
DNA balance_sheet (annual, 2023-12-31) — Working Capital: 837889000.00
DNA cash_flow (quarterly, 2024-09-30) — Asset Impairment Charge: 0.00
DNA income_statement (quarterly, 2024-09-30) — Earnings From Equity Interest: 0.00
DNA cash_flow (quarterly, 2024-09-30) — Gain Loss On Investment Securities: 14754000.00
DNA income_statement (quarterly, 2024-09-30) — Gain On Sale Of Business: -7013000.00
DNA balance_sheet (quarterly, 2024-09-30) — Goodwill: 0.00
DNA income_statement (quarterly, 2024-09-30) — Impairment Of Capital Assets: 0.00
DNA cash_flow (quarterly, 2024-09-30) — Net Other Financing Charges: -265000.00
DNA income_statement (quarterly, 2024-09-30) — Otherunder Preferred Stock Dividend: 29000.00
DNA cash_flow (quarterly, 2024-09-30) — Sale Of PPE: 400000.00
DNA income_statement (quarterly, 2024-09-30) — Write Off: 0.00
DNA income_statement (annual, 2024-12-31) — +Operating Expense: 670222000.00
DNA income_statement (annual, 2024-12-31) — +Total Revenue: 227043000.00
DNA balance_sheet (annual, 2024-12-31) — Accounts Payable: 14169000.00
DNA balance_sheet (annual, 2024-12-31) — Accounts Receivable: 21857000.00
DNA balance_sheet (annual, 2024-12-31) — Accumulated Depreciation: -160872000.00
DNA balance_sheet (annual, 2024-12-31) — Additional Paid In Capital: 6555416000.00
DNA cash_flow (annual, 2024-12-31) — Amortization Of Securities: 0.00
DNA cash_flow (annual, 2024-12-31) — Asset Impairment Charge: 58477000.00
DNA cash_flow (quarterly, 2024-12-31) — Asset Impairment Charge: 5796000.00
DNA balance_sheet (annual, 2024-12-31) — Available For Sale Securities: 31777000.00
DNA income_statement (annual, 2024-12-31) — Basic Average Shares: 51894639.00
DNA income_statement (quarterly, 2024-12-31) — Basic Average Shares: 53814706.00
DNA income_statement (annual, 2024-12-31) — Basic EPS: -10.54
DNA income_statement (quarterly, 2024-12-31) — Basic EPS: -2.00
DNA cash_flow (annual, 2024-12-31) — Beginning Cash Position: 989584000.00
DNA balance_sheet (annual, 2024-12-31) — Buildings And Improvements: 48255000.00
DNA cash_flow (annual, 2024-12-31) — Capital Expenditure: -62541000.00
DNA cash_flow (quarterly, 2024-12-31) — Capital Expenditure: -13710000.00
DNA balance_sheet (annual, 2024-12-31) — Capital Lease Obligations: 467731000.00
DNA balance_sheet (annual, 2024-12-31) — Capital Stock: 5000.00
DNA balance_sheet (annual, 2024-12-31) — Cash And Cash Equivalents: 561572000.00
DNA balance_sheet (annual, 2024-12-31) — Cash Cash Equivalents And Short Term Investments: 561572000.00
DNA cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Financing Activities: -1739000.00
DNA cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Investing Activities: -62236000.00
DNA cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Operating Activities: -319585000.00
DNA cash_flow (annual, 2024-12-31) — Change In Account Payable: 4771000.00
DNA cash_flow (quarterly, 2024-12-31) — Change In Account Payable: 35870000.00
DNA cash_flow (annual, 2024-12-31) — Change In Accrued Expense: -40438000.00
DNA cash_flow (annual, 2024-12-31) — Change In Other Current Assets: 22069000.00
DNA cash_flow (annual, 2024-12-31) — Change In Other Current Liabilities: -12787000.00
DNA cash_flow (annual, 2024-12-31) — Change In Other Working Capital: -68645000.00
DNA cash_flow (annual, 2024-12-31) — Change In Payable: 4771000.00
DNA cash_flow (quarterly, 2024-12-31) — Change In Payable: 35870000.00
DNA cash_flow (annual, 2024-12-31) — Change In Payables And Accrued Expense: -35667000.00
DNA cash_flow (annual, 2024-12-31) — Change In Prepaid Assets: 10085000.00
DNA cash_flow (annual, 2024-12-31) — Change In Receivables: -4725000.00
DNA cash_flow (annual, 2024-12-31) — Change In Working Capital: -89670000.00
DNA cash_flow (annual, 2024-12-31) — Changes In Account Receivables: -4725000.00
DNA cash_flow (annual, 2024-12-31) — Changes In Cash: -383560000.00
DNA balance_sheet (annual, 2024-12-31) — Common Stock: 5000.00
DNA balance_sheet (annual, 2024-12-31) — Common Stock Equity: 716058000.00
DNA cash_flow (annual, 2024-12-31) — Common Stock Issuance: 0.00
DNA balance_sheet (annual, 2024-12-31) — Construction In Progress: 1984000.00
DNA income_statement (annual, 2024-12-31) — Cost Of Revenue: 44548000.00
DNA balance_sheet (annual, 2024-12-31) — Current Accrued Expenses: 6912000.00
DNA balance_sheet (annual, 2024-12-31) — Current Assets: 602744000.00
DNA balance_sheet (annual, 2024-12-31) — Current Capital Lease Obligation: 28965000.00
DNA balance_sheet (quarterly, 2024-12-31) — Current Capital Lease Obligation: 28965000.00
DNA balance_sheet (annual, 2024-12-31) — Current Debt And Capital Lease Obligation: 28965000.00
DNA balance_sheet (quarterly, 2024-12-31) — Current Debt And Capital Lease Obligation: 28965000.00
DNA balance_sheet (annual, 2024-12-31) — Current Deferred Liabilities: 30599000.00
DNA balance_sheet (annual, 2024-12-31) — Current Deferred Revenue: 30599000.00
DNA balance_sheet (annual, 2024-12-31) — Current Liabilities: 107266000.00
DNA cash_flow (annual, 2024-12-31) — Deferred Income Tax: -936000.00
DNA cash_flow (annual, 2024-12-31) — Deferred Tax: -936000.00
DNA cash_flow (annual, 2024-12-31) — Depreciation Amortization Depletion: 63020000.00
DNA cash_flow (annual, 2024-12-31) — Depreciation And Amortization: 63020000.00
DNA income_statement (annual, 2024-12-31) — Diluted Average Shares: 51894639.00
DNA income_statement (quarterly, 2024-12-31) — Diluted Average Shares: 53814706.00
DNA income_statement (annual, 2024-12-31) — Diluted EPS: -10.54
DNA income_statement (quarterly, 2024-12-31) — Diluted EPS: -2.00
DNA income_statement (annual, 2024-12-31) — Diluted NI Availto Com Stockholders: -547029000.00
DNA balance_sheet (annual, 2024-12-31) — Duefrom Related Parties Current: 586000.00
DNA income_statement (annual, 2024-12-31) — EBIT: -547414000.00
DNA income_statement (annual, 2024-12-31) — EBITDA: -484394000.00
DNA income_statement (annual, 2024-12-31) — Earnings From Equity Interest: 0.00
DNA income_statement (quarterly, 2024-12-31) — Earnings From Equity Interest: 0.00
DNA cash_flow (annual, 2024-12-31) — Earnings Losses From Equity Investments: 0.00
DNA cash_flow (annual, 2024-12-31) — Effect Of Exchange Rate Changes: -281000.00
DNA cash_flow (annual, 2024-12-31) — End Cash Position: 605743000.00
DNA balance_sheet (annual, 2024-12-31) — Financial Assets: 238000.00
DNA cash_flow (annual, 2024-12-31) — Financing Cash Flow: -1739000.00
DNA cash_flow (annual, 2024-12-31) — Free Cash Flow: -382126000.00
DNA cash_flow (annual, 2024-12-31) — Gain Loss On Investment Securities: 23126000.00
DNA cash_flow (quarterly, 2024-12-31) — Gain Loss On Investment Securities: 12545000.00
DNA cash_flow (annual, 2024-12-31) — Gain Loss On Sale Of Business: 7013000.00
DNA cash_flow (quarterly, 2024-12-31) — Gain Loss On Sale Of Business: 0.00
DNA cash_flow (annual, 2024-12-31) — Gain Loss On Sale Of PPE: 844000.00
DNA income_statement (annual, 2024-12-31) — Gain On Sale Of Business: -7013000.00
DNA income_statement (quarterly, 2024-12-31) — Gain On Sale Of Business: 0.00
DNA income_statement (annual, 2024-12-31) — Gain On Sale Of Security: -23126000.00
DNA balance_sheet (annual, 2024-12-31) — Gains Losses Not Affecting Retained Earnings: -1806000.00
DNA income_statement (annual, 2024-12-31) — General And Administrative Expense: 246161000.00
DNA balance_sheet (annual, 2024-12-31) — Goodwill: 0.00
DNA balance_sheet (quarterly, 2024-12-31) — Goodwill: 0.00
DNA balance_sheet (annual, 2024-12-31) — Goodwill And Other Intangible Assets: 72510000.00
DNA balance_sheet (annual, 2024-12-31) — Gross PPE: 759027000.00
DNA income_statement (annual, 2024-12-31) — Gross Profit: 182495000.00
DNA income_statement (annual, 2024-12-31) — Impairment Of Capital Assets: 47858000.00
DNA income_statement (quarterly, 2024-12-31) — Impairment Of Capital Assets: 0.00
DNA cash_flow (annual, 2024-12-31) — Income Tax Paid Supplemental Data: 894000.00
DNA income_statement (annual, 2024-12-31) — Interest Expense: 94000.00
DNA income_statement (annual, 2024-12-31) — Interest Expense Non Operating: 94000.00
DNA income_statement (annual, 2024-12-31) — Interest Income: 38612000.00
DNA income_statement (annual, 2024-12-31) — Interest Income Non Operating: 38612000.00
DNA cash_flow (annual, 2024-12-31) — Interest Paid Supplemental Data: 32000.00
DNA balance_sheet (annual, 2024-12-31) — Invested Capital: 716058000.00
DNA cash_flow (annual, 2024-12-31) — Investing Cash Flow: -62236000.00
DNA balance_sheet (annual, 2024-12-31) — Investmentin Financial Assets: 31777000.00
DNA balance_sheet (annual, 2024-12-31) — Investments And Advances: 48466000.00
DNA cash_flow (annual, 2024-12-31) — Issuance Of Capital Stock: 0.00
DNA balance_sheet (annual, 2024-12-31) — Land And Improvements: 6060000.00
DNA balance_sheet (annual, 2024-12-31) — Leases: 135964000.00
DNA balance_sheet (annual, 2024-12-31) — Long Term Capital Lease Obligation: 438766000.00
DNA balance_sheet (annual, 2024-12-31) — Long Term Debt And Capital Lease Obligation: 438766000.00
DNA cash_flow (annual, 2024-12-31) — Long Term Debt Payments: -897000.00
DNA balance_sheet (annual, 2024-12-31) — Machinery Furniture Equipment: 21442000.00
DNA balance_sheet (annual, 2024-12-31) — Minority Interest: 0.00
DNA balance_sheet (quarterly, 2024-12-31) — Minority Interest: 0.00
DNA income_statement (annual, 2024-12-31) — Minority Interests: 0.00
DNA cash_flow (annual, 2024-12-31) — Net Business Purchase And Sale: -5400000.00
DNA cash_flow (quarterly, 2024-12-31) — Net Business Purchase And Sale: 0.00
DNA cash_flow (annual, 2024-12-31) — Net Common Stock Issuance: 0.00
DNA income_statement (annual, 2024-12-31) — Net Income: -547029000.00
DNA income_statement (annual, 2024-12-31) — Net Income Common Stockholders: -547029000.00
DNA income_statement (annual, 2024-12-31) — Net Income Continuous Operations: -547029000.00
DNA income_statement (annual, 2024-12-31) — Net Income From Continuing And Discontinued Operation: -547029000.00
DNA income_statement (annual, 2024-12-31) — Net Income From Continuing Operation Net Minority Interest: -547029000.00
DNA cash_flow (annual, 2024-12-31) — Net Income From Continuing Operations: -547029000.00
DNA income_statement (annual, 2024-12-31) — Net Income Including Noncontrolling Interests: -547029000.00
DNA income_statement (annual, 2024-12-31) — Net Interest Income: 38518000.00
DNA cash_flow (annual, 2024-12-31) — Net Investment Purchase And Sale: 4519000.00
DNA cash_flow (annual, 2024-12-31) — Net Issuance Payments Of Debt: -897000.00
DNA cash_flow (annual, 2024-12-31) — Net Long Term Debt Issuance: -897000.00
DNA income_statement (annual, 2024-12-31) — Net Non Operating Interest Income Expense: 38518000.00
DNA cash_flow (annual, 2024-12-31) — Net Other Financing Charges: -926000.00
DNA cash_flow (quarterly, 2024-12-31) — Net Other Financing Charges: 0.00
DNA cash_flow (annual, 2024-12-31) — Net Other Investing Changes: 538000.00
DNA balance_sheet (annual, 2024-12-31) — Net PPE: 598155000.00
DNA cash_flow (annual, 2024-12-31) — Net PPE Purchase And Sale: -61893000.00
DNA balance_sheet (annual, 2024-12-31) — Net Tangible Assets: 643548000.00
DNA balance_sheet (annual, 2024-12-31) — Non Current Deferred Liabilities: 98783000.00
DNA balance_sheet (annual, 2024-12-31) — Non Current Deferred Revenue: 98783000.00
DNA income_statement (annual, 2024-12-31) — Normalized EBITDA: -382225000.00
DNA income_statement (annual, 2024-12-31) — Normalized Income: -444962169.00
DNA cash_flow (annual, 2024-12-31) — Operating Cash Flow: -319585000.00
DNA cash_flow (annual, 2024-12-31) — Operating Gains Losses: 30983000.00
DNA income_statement (annual, 2024-12-31) — Operating Income: -487727000.00
DNA income_statement (annual, 2024-12-31) — Operating Revenue: 227043000.00
DNA balance_sheet (annual, 2024-12-31) — Ordinary Shares Number: 54365785.00
DNA balance_sheet (annual, 2024-12-31) — Other Current Assets: 18729000.00
DNA balance_sheet (annual, 2024-12-31) — Other Current Liabilities: 14340000.00
DNA balance_sheet (quarterly, 2024-12-31) — Other Current Liabilities: 14340000.00
DNA balance_sheet (annual, 2024-12-31) — Other Equity Adjustments: -1806000.00
DNA income_statement (annual, 2024-12-31) — Other Gand A: 246161000.00
DNA income_statement (annual, 2024-12-31) — Other Income Expense: -98299000.00
DNA balance_sheet (annual, 2024-12-31) — Other Intangible Assets: 72510000.00
DNA balance_sheet (annual, 2024-12-31) — Other Investments: 16689000.00
DNA cash_flow (annual, 2024-12-31) — Other Non Cash Items: 53226000.00
DNA balance_sheet (annual, 2024-12-31) — Other Non Current Assets: 55336000.00
DNA balance_sheet (annual, 2024-12-31) — Other Non Current Liabilities: 16576000.00
DNA income_statement (annual, 2024-12-31) — Other Non Operating Income Expenses: 3870000.00
DNA balance_sheet (annual, 2024-12-31) — Other Properties: 545322000.00
DNA balance_sheet (annual, 2024-12-31) — Other Short Term Investments: 0.00
DNA balance_sheet (annual, 2024-12-31) — Payables: 14169000.00
DNA balance_sheet (annual, 2024-12-31) — Payables And Accrued Expenses: 21081000.00
DNA balance_sheet (annual, 2024-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 12281000.00
DNA balance_sheet (quarterly, 2024-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 12281000.00
DNA balance_sheet (annual, 2024-12-31) — Preferred Stock: 0.00
DNA income_statement (annual, 2024-12-31) — Pretax Income: -547508000.00
DNA cash_flow (annual, 2024-12-31) — Proceeds From Stock Option Exercised: 84000.00
DNA cash_flow (quarterly, 2024-12-31) — Proceeds From Stock Option Exercised: 0.00
DNA balance_sheet (annual, 2024-12-31) — Properties: 0.00
DNA cash_flow (annual, 2024-12-31) — Purchase Of Business: -5400000.00
DNA cash_flow (quarterly, 2024-12-31) — Purchase Of Business: 0.00
DNA cash_flow (annual, 2024-12-31) — Purchase Of Investment: 0.00
DNA cash_flow (annual, 2024-12-31) — Purchase Of PPE: -62541000.00
DNA balance_sheet (annual, 2024-12-31) — Receivables: 22443000.00
DNA income_statement (annual, 2024-12-31) — Reconciled Cost Of Revenue: 44548000.00
DNA income_statement (annual, 2024-12-31) — Reconciled Depreciation: 63020000.00
DNA cash_flow (annual, 2024-12-31) — Repayment Of Debt: -897000.00
DNA income_statement (annual, 2024-12-31) — Research And Development: 424061000.00
DNA income_statement (annual, 2024-12-31) — Restructuring And Mergern Acquisition: 24172000.00
DNA balance_sheet (annual, 2024-12-31) — Retained Earnings: -5837557000.00
DNA cash_flow (annual, 2024-12-31) — Sale Of Investment: 4519000.00
DNA cash_flow (annual, 2024-12-31) — Sale Of PPE: 648000.00
DNA cash_flow (quarterly, 2024-12-31) — Sale Of PPE: 57000.00
DNA income_statement (annual, 2024-12-31) — Selling General And Administration: 246161000.00
DNA balance_sheet (annual, 2024-12-31) — Share Issued: 54365785.00
DNA income_statement (annual, 2024-12-31) — Special Income Charges: -79043000.00
DNA cash_flow (annual, 2024-12-31) — Stock Based Compensation: 112344000.00
DNA balance_sheet (annual, 2024-12-31) — Stockholders Equity: 716058000.00
DNA balance_sheet (annual, 2024-12-31) — Tangible Book Value: 643548000.00
DNA income_statement (annual, 2024-12-31) — Tax Effect Of Unusual Items: -102169.00
DNA income_statement (annual, 2024-12-31) — Tax Provision: -479000.00
DNA income_statement (annual, 2024-12-31) — Tax Rate For Calcs: 0.00
DNA balance_sheet (annual, 2024-12-31) — Total Assets: 1377449000.00
DNA balance_sheet (annual, 2024-12-31) — Total Capitalization: 716058000.00
DNA balance_sheet (annual, 2024-12-31) — Total Debt: 467731000.00
DNA balance_sheet (annual, 2024-12-31) — Total Equity Gross Minority Interest: 716058000.00
DNA income_statement (annual, 2024-12-31) — Total Expenses: 714770000.00
DNA balance_sheet (annual, 2024-12-31) — Total Liabilities Net Minority Interest: 661391000.00
DNA balance_sheet (annual, 2024-12-31) — Total Non Current Assets: 774705000.00
DNA balance_sheet (annual, 2024-12-31) — Total Non Current Liabilities Net Minority Interest: 554125000.00
DNA income_statement (annual, 2024-12-31) — Total Operating Income As Reported: -559757000.00
DNA income_statement (annual, 2024-12-31) — Total Unusual Items: -102169000.00
DNA income_statement (annual, 2024-12-31) — Total Unusual Items Excluding Goodwill: -102169000.00
DNA balance_sheet (annual, 2024-12-31) — Working Capital: 495478000.00
DNA income_statement (quarterly, 2025-03-31) — +Operating Expense: 110646000.00
DNA income_statement (quarterly, 2025-03-31) — +Total Revenue: 38230000.00
DNA balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 11267000.00
DNA balance_sheet (quarterly, 2025-03-31) — Accounts Receivable: 26293000.00
DNA balance_sheet (quarterly, 2025-03-31) — Accumulated Depreciation: -163421000.00
DNA balance_sheet (quarterly, 2025-03-31) — Additional Paid In Capital: 6576786000.00
DNA cash_flow (quarterly, 2025-03-31) — Amortization Of Securities: 0.00
DNA balance_sheet (quarterly, 2025-03-31) — Available For Sale Securities: 15273000.00
DNA income_statement (quarterly, 2025-03-31) — Basic Average Shares: 54241619.00
DNA income_statement (quarterly, 2025-03-31) — Basic EPS: -1.68
DNA cash_flow (quarterly, 2025-03-31) — Beginning Cash Position: 605743000.00
DNA balance_sheet (quarterly, 2025-03-31) — Buildings And Improvements: 48294000.00
DNA cash_flow (quarterly, 2025-03-31) — Capital Expenditure: -7622000.00
DNA balance_sheet (quarterly, 2025-03-31) — Capital Lease Obligations: 434561000.00
DNA balance_sheet (quarterly, 2025-03-31) — Capital Stock: 5000.00
DNA balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 312420000.00
DNA balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 516922000.00
DNA cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Financing Activities: -207000.00
DNA cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Investing Activities: -198684000.00
DNA cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Operating Activities: -42749000.00
DNA cash_flow (quarterly, 2025-03-31) — Change In Other Current Assets: 3508000.00
DNA cash_flow (quarterly, 2025-03-31) — Change In Other Current Liabilities: -4790000.00
DNA cash_flow (quarterly, 2025-03-31) — Change In Other Working Capital: -13190000.00
DNA cash_flow (quarterly, 2025-03-31) — Change In Payables And Accrued Expense: 8869000.00
DNA cash_flow (quarterly, 2025-03-31) — Change In Prepaid Assets: -581000.00
DNA cash_flow (quarterly, 2025-03-31) — Change In Receivables: -667000.00
DNA cash_flow (quarterly, 2025-03-31) — Change In Working Capital: -6851000.00
DNA cash_flow (quarterly, 2025-03-31) — Changes In Account Receivables: -667000.00
DNA cash_flow (quarterly, 2025-03-31) — Changes In Cash: -250412000.00
DNA balance_sheet (quarterly, 2025-03-31) — Common Stock: 5000.00
DNA balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 647427000.00
DNA balance_sheet (quarterly, 2025-03-31) — Construction In Progress: 1453000.00
DNA income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 4090000.00
DNA balance_sheet (quarterly, 2025-03-31) — Current Accrued Expenses: 70747000.00
DNA balance_sheet (quarterly, 2025-03-31) — Current Assets: 564534000.00
DNA balance_sheet (quarterly, 2025-03-31) — Current Deferred Liabilities: 33653000.00
DNA balance_sheet (quarterly, 2025-03-31) — Current Deferred Revenue: 33653000.00
DNA balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 115667000.00
DNA cash_flow (quarterly, 2025-03-31) — Depreciation Amortization Depletion: 14822000.00
DNA cash_flow (quarterly, 2025-03-31) — Depreciation And Amortization: 14822000.00
DNA income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 54241619.00
DNA income_statement (quarterly, 2025-03-31) — Diluted EPS: -1.68
DNA income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: -90957000.00
DNA balance_sheet (quarterly, 2025-03-31) — Duefrom Related Parties Current: 877000.00
DNA income_statement (quarterly, 2025-03-31) — EBIT: -76506000.00
DNA income_statement (quarterly, 2025-03-31) — EBITDA: -61684000.00
DNA cash_flow (quarterly, 2025-03-31) — Effect Of Exchange Rate Changes: 74000.00
DNA cash_flow (quarterly, 2025-03-31) — End Cash Position: 355405000.00
DNA balance_sheet (quarterly, 2025-03-31) — Financial Assets: 211000.00
DNA cash_flow (quarterly, 2025-03-31) — Financing Cash Flow: -207000.00
DNA cash_flow (quarterly, 2025-03-31) — Free Cash Flow: -59143000.00
DNA cash_flow (quarterly, 2025-03-31) — Gain Loss On Investment Securities: 3693000.00
DNA income_statement (quarterly, 2025-03-31) — Gain On Sale Of Security: -1849000.00
DNA balance_sheet (quarterly, 2025-03-31) — Gains Losses Not Affecting Retained Earnings: -850000.00
DNA income_statement (quarterly, 2025-03-31) — General And Administrative Expense: 39723000.00
DNA balance_sheet (quarterly, 2025-03-31) — Goodwill And Other Intangible Assets: 68756000.00
DNA balance_sheet (quarterly, 2025-03-31) — Gross PPE: 744643000.00
DNA income_statement (quarterly, 2025-03-31) — Gross Profit: 34140000.00
DNA income_statement (quarterly, 2025-03-31) — Interest Income: 6081000.00
DNA income_statement (quarterly, 2025-03-31) — Interest Income Non Operating: 6081000.00
DNA balance_sheet (quarterly, 2025-03-31) — Invested Capital: 647427000.00
DNA cash_flow (quarterly, 2025-03-31) — Investing Cash Flow: -198684000.00
DNA balance_sheet (quarterly, 2025-03-31) — Investmentin Financial Assets: 15273000.00
DNA balance_sheet (quarterly, 2025-03-31) — Investments And Advances: 31962000.00
DNA balance_sheet (quarterly, 2025-03-31) — Land And Improvements: 6060000.00
DNA balance_sheet (quarterly, 2025-03-31) — Leases: 140407000.00
DNA balance_sheet (quarterly, 2025-03-31) — Long Term Capital Lease Obligation: 434561000.00
DNA balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 434561000.00
DNA cash_flow (quarterly, 2025-03-31) — Long Term Debt Payments: -207000.00
DNA balance_sheet (quarterly, 2025-03-31) — Machinery Furniture Equipment: 16220000.00
DNA cash_flow (quarterly, 2025-03-31) — Net Business Purchase And Sale: 0.00
DNA income_statement (quarterly, 2025-03-31) — Net Income: -90957000.00
DNA income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: -90957000.00
DNA income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: -83310000.00
DNA income_statement (quarterly, 2025-03-31) — Net Income Discontinuous Operations: -7647000.00
DNA income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: -90957000.00
DNA income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: -83310000.00
DNA cash_flow (quarterly, 2025-03-31) — Net Income From Continuing Operations: -83310000.00
DNA income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: -90957000.00
DNA income_statement (quarterly, 2025-03-31) — Net Interest Income: 6081000.00
DNA cash_flow (quarterly, 2025-03-31) — Net Investment Purchase And Sale: -191182000.00
DNA cash_flow (quarterly, 2025-03-31) — Net Issuance Payments Of Debt: -207000.00
DNA cash_flow (quarterly, 2025-03-31) — Net Long Term Debt Issuance: -207000.00
DNA income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: 6081000.00
DNA cash_flow (quarterly, 2025-03-31) — Net Other Investing Changes: 120000.00
DNA balance_sheet (quarterly, 2025-03-31) — Net PPE: 581222000.00
DNA cash_flow (quarterly, 2025-03-31) — Net PPE Purchase And Sale: -7622000.00
DNA balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: 578671000.00
DNA balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Liabilities: 80378000.00
DNA balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Revenue: 80378000.00
DNA income_statement (quarterly, 2025-03-31) — Normalized EBITDA: -53525000.00
DNA income_statement (quarterly, 2025-03-31) — Normalized Income: -76864390.00
DNA cash_flow (quarterly, 2025-03-31) — Operating Cash Flow: -51521000.00
DNA cash_flow (quarterly, 2025-03-31) — Operating Gains Losses: 3693000.00
DNA income_statement (quarterly, 2025-03-31) — Operating Income: -76506000.00
DNA income_statement (quarterly, 2025-03-31) — Operating Revenue: 38230000.00
DNA balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 54698246.00
DNA balance_sheet (quarterly, 2025-03-31) — Other Current Assets: 20442000.00
DNA balance_sheet (quarterly, 2025-03-31) — Other Equity Adjustments: -850000.00
DNA income_statement (quarterly, 2025-03-31) — Other Gand A: 39723000.00
DNA income_statement (quarterly, 2025-03-31) — Other Income Expense: -12797000.00
DNA balance_sheet (quarterly, 2025-03-31) — Other Intangible Assets: 68756000.00
DNA balance_sheet (quarterly, 2025-03-31) — Other Investments: 16689000.00
DNA cash_flow (quarterly, 2025-03-31) — Other Non Cash Items: 2739000.00
DNA balance_sheet (quarterly, 2025-03-31) — Other Non Current Assets: 46778000.00
DNA balance_sheet (quarterly, 2025-03-31) — Other Non Current Liabilities: 15430000.00
DNA income_statement (quarterly, 2025-03-31) — Other Non Operating Income Expenses: -4638000.00
DNA balance_sheet (quarterly, 2025-03-31) — Other Properties: 532209000.00
DNA balance_sheet (quarterly, 2025-03-31) — Other Short Term Investments: 204502000.00
DNA income_statement (quarterly, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
DNA balance_sheet (quarterly, 2025-03-31) — Payables: 11267000.00
DNA balance_sheet (quarterly, 2025-03-31) — Payables And Accrued Expenses: 82014000.00
DNA balance_sheet (quarterly, 2025-03-31) — Preferred Stock: 0.00
DNA income_statement (quarterly, 2025-03-31) — Pretax Income: -83222000.00
DNA cash_flow (quarterly, 2025-03-31) — Proceeds From Stock Option Exercised: 0.00
DNA balance_sheet (quarterly, 2025-03-31) — Properties: 0.00
DNA cash_flow (quarterly, 2025-03-31) — Purchase Of Business: 0.00
DNA cash_flow (quarterly, 2025-03-31) — Purchase Of Investment: -191182000.00
DNA cash_flow (quarterly, 2025-03-31) — Purchase Of PPE: -7622000.00
DNA balance_sheet (quarterly, 2025-03-31) — Receivables: 27170000.00
DNA income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 4090000.00
DNA income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 14822000.00
DNA cash_flow (quarterly, 2025-03-31) — Repayment Of Debt: -207000.00
DNA income_statement (quarterly, 2025-03-31) — Research And Development: 70923000.00
DNA income_statement (quarterly, 2025-03-31) — Restructuring And Mergern Acquisition: 4466000.00
DNA balance_sheet (quarterly, 2025-03-31) — Retained Earnings: -5928514000.00
DNA cash_flow (quarterly, 2025-03-31) — Sale Of Investment: 0.00
DNA income_statement (quarterly, 2025-03-31) — Selling General And Administration: 39723000.00
DNA balance_sheet (quarterly, 2025-03-31) — Share Issued: 54698246.00
DNA income_statement (quarterly, 2025-03-31) — Special Income Charges: -6310000.00
DNA cash_flow (quarterly, 2025-03-31) — Stock Based Compensation: 17386000.00
DNA balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 647427000.00
DNA balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: 578671000.00
DNA income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: -1713390.00
DNA income_statement (quarterly, 2025-03-31) — Tax Provision: 88000.00
DNA income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.21
DNA balance_sheet (quarterly, 2025-03-31) — Total Assets: 1293463000.00
DNA balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 647427000.00
DNA balance_sheet (quarterly, 2025-03-31) — Total Debt: 434561000.00
DNA balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 647427000.00
DNA income_statement (quarterly, 2025-03-31) — Total Expenses: 114736000.00
DNA balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 646036000.00
DNA balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 728929000.00
DNA balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 530369000.00
DNA income_statement (quarterly, 2025-03-31) — Total Operating Income As Reported: -80972000.00
DNA income_statement (quarterly, 2025-03-31) — Total Unusual Items: -8159000.00
DNA income_statement (quarterly, 2025-03-31) — Total Unusual Items Excluding Goodwill: -8159000.00
DNA balance_sheet (quarterly, 2025-03-31) — Working Capital: 448867000.00
DNA income_statement (quarterly, 2025-03-31) — Write Off: 1844000.00
DNA income_statement (quarterly, 2025-06-30) — +Operating Expense: 96649000.00
DNA income_statement (quarterly, 2025-06-30) — +Total Revenue: 49604000.00
DNA balance_sheet (quarterly, 2025-06-30) — Accounts Payable: 11202000.00
DNA balance_sheet (quarterly, 2025-06-30) — Accounts Receivable: 22152000.00
DNA balance_sheet (quarterly, 2025-06-30) — Accumulated Depreciation: -173495000.00
DNA balance_sheet (quarterly, 2025-06-30) — Additional Paid In Capital: 6600107000.00
DNA balance_sheet (quarterly, 2025-06-30) — Available For Sale Securities: 15757000.00
DNA income_statement (quarterly, 2025-06-30) — Basic Average Shares: 54858982.00
DNA income_statement (quarterly, 2025-06-30) — Basic EPS: -1.10
DNA cash_flow (quarterly, 2025-06-30) — Beginning Cash Position: 355405000.00
DNA balance_sheet (quarterly, 2025-06-30) — Buildings And Improvements: 49760000.00
DNA cash_flow (quarterly, 2025-06-30) — Capital Expenditure: -38000.00
DNA balance_sheet (quarterly, 2025-06-30) — Capital Lease Obligations: 428827000.00
DNA balance_sheet (quarterly, 2025-06-30) — Capital Stock: 6000.00
DNA balance_sheet (quarterly, 2025-06-30) — Cash And Cash Equivalents: 203566000.00
DNA balance_sheet (quarterly, 2025-06-30) — Cash Cash Equivalents And Short Term Investments: 473691000.00
DNA cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Financing Activities: -98000.00
DNA cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Investing Activities: -63888000.00
DNA cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Operating Activities: -49026000.00
DNA cash_flow (quarterly, 2025-06-30) — Change In Other Current Assets: 181000.00
DNA cash_flow (quarterly, 2025-06-30) — Change In Other Current Liabilities: -1692000.00
DNA cash_flow (quarterly, 2025-06-30) — Change In Other Working Capital: -10486000.00
DNA cash_flow (quarterly, 2025-06-30) — Change In Payables And Accrued Expense: -13994000.00
DNA cash_flow (quarterly, 2025-06-30) — Change In Prepaid Assets: -1691000.00
DNA cash_flow (quarterly, 2025-06-30) — Change In Receivables: 255000.00
DNA cash_flow (quarterly, 2025-06-30) — Change In Working Capital: -27427000.00
DNA cash_flow (quarterly, 2025-06-30) — Changes In Account Receivables: 255000.00
DNA cash_flow (quarterly, 2025-06-30) — Changes In Cash: -104240000.00
DNA balance_sheet (quarterly, 2025-06-30) — Common Stock: 6000.00
DNA balance_sheet (quarterly, 2025-06-30) — Common Stock Equity: 612952000.00
DNA balance_sheet (quarterly, 2025-06-30) — Construction In Progress: 0.00
DNA income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 14822000.00
DNA balance_sheet (quarterly, 2025-06-30) — Current Accrued Expenses: 57231000.00
DNA balance_sheet (quarterly, 2025-06-30) — Current Assets: 523025000.00
DNA balance_sheet (quarterly, 2025-06-30) — Current Deferred Liabilities: 28287000.00
DNA balance_sheet (quarterly, 2025-06-30) — Current Deferred Revenue: 28287000.00
DNA balance_sheet (quarterly, 2025-06-30) — Current Liabilities: 96720000.00
DNA cash_flow (quarterly, 2025-06-30) — Depreciation Amortization Depletion: 16337000.00
DNA cash_flow (quarterly, 2025-06-30) — Depreciation And Amortization: 16337000.00
DNA income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 54858982.00
DNA income_statement (quarterly, 2025-06-30) — Diluted EPS: -1.10
DNA income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: -60300000.00
DNA balance_sheet (quarterly, 2025-06-30) — Duefrom Related Parties Current: 974000.00
DNA income_statement (quarterly, 2025-06-30) — EBIT: -61867000.00
DNA income_statement (quarterly, 2025-06-30) — EBITDA: -45530000.00
DNA cash_flow (quarterly, 2025-06-30) — Effect Of Exchange Rate Changes: 186000.00
DNA cash_flow (quarterly, 2025-06-30) — End Cash Position: 251351000.00
DNA balance_sheet (quarterly, 2025-06-30) — Financial Assets: 216000.00
DNA cash_flow (quarterly, 2025-06-30) — Financing Cash Flow: -98000.00
DNA cash_flow (quarterly, 2025-06-30) — Free Cash Flow: -40292000.00
DNA income_statement (quarterly, 2025-06-30) — Gain On Sale Of Security: -229000.00
DNA balance_sheet (quarterly, 2025-06-30) — Gains Losses Not Affecting Retained Earnings: 1653000.00
DNA income_statement (quarterly, 2025-06-30) — General And Administrative Expense: 43279000.00
DNA balance_sheet (quarterly, 2025-06-30) — Goodwill And Other Intangible Assets: 66152000.00
DNA balance_sheet (quarterly, 2025-06-30) — Gross PPE: 735645000.00
DNA income_statement (quarterly, 2025-06-30) — Gross Profit: 34782000.00
DNA income_statement (quarterly, 2025-06-30) — Impairment Of Capital Assets: 0.00
DNA income_statement (quarterly, 2025-06-30) — Interest Income: 6083000.00
DNA income_statement (quarterly, 2025-06-30) — Interest Income Non Operating: 6083000.00
DNA balance_sheet (quarterly, 2025-06-30) — Invested Capital: 612952000.00
DNA cash_flow (quarterly, 2025-06-30) — Investing Cash Flow: -63888000.00
DNA balance_sheet (quarterly, 2025-06-30) — Investmentin Financial Assets: 15757000.00
DNA balance_sheet (quarterly, 2025-06-30) — Investments And Advances: 32446000.00
DNA balance_sheet (quarterly, 2025-06-30) — Land And Improvements: 6060000.00
DNA balance_sheet (quarterly, 2025-06-30) — Leases: 140453000.00
DNA balance_sheet (quarterly, 2025-06-30) — Long Term Capital Lease Obligation: 428827000.00
DNA balance_sheet (quarterly, 2025-06-30) — Long Term Debt And Capital Lease Obligation: 428827000.00
DNA cash_flow (quarterly, 2025-06-30) — Long Term Debt Payments: -98000.00
DNA balance_sheet (quarterly, 2025-06-30) — Machinery Furniture Equipment: 15684000.00
DNA cash_flow (quarterly, 2025-06-30) — Net Business Purchase And Sale: 0.00
DNA income_statement (quarterly, 2025-06-30) — Net Income: -60300000.00
DNA income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: -60300000.00
DNA income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: -60300000.00
DNA income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: -60300000.00
DNA income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: -60300000.00
DNA cash_flow (quarterly, 2025-06-30) — Net Income From Continuing Operations: -67947000.00
DNA income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: -60300000.00
DNA income_statement (quarterly, 2025-06-30) — Net Interest Income: 6083000.00
DNA cash_flow (quarterly, 2025-06-30) — Net Investment Purchase And Sale: -63992000.00
DNA cash_flow (quarterly, 2025-06-30) — Net Issuance Payments Of Debt: -98000.00
DNA cash_flow (quarterly, 2025-06-30) — Net Long Term Debt Issuance: -98000.00
DNA income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: 6083000.00
DNA cash_flow (quarterly, 2025-06-30) — Net Other Investing Changes: 142000.00
DNA balance_sheet (quarterly, 2025-06-30) — Net PPE: 562150000.00
DNA cash_flow (quarterly, 2025-06-30) — Net PPE Purchase And Sale: -38000.00
DNA balance_sheet (quarterly, 2025-06-30) — Net Tangible Assets: 546800000.00
DNA balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Liabilities: 74566000.00
DNA balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Revenue: 74566000.00
DNA income_statement (quarterly, 2025-06-30) — Normalized EBITDA: -41627000.00
DNA income_statement (quarterly, 2025-06-30) — Normalized Income: -56415232.00
DNA cash_flow (quarterly, 2025-06-30) — Operating Cash Flow: -40254000.00
DNA cash_flow (quarterly, 2025-06-30) — Operating Gains Losses: 265000.00
DNA income_statement (quarterly, 2025-06-30) — Operating Income: -61867000.00
DNA income_statement (quarterly, 2025-06-30) — Operating Revenue: 49604000.00
DNA balance_sheet (quarterly, 2025-06-30) — Ordinary Shares Number: 55425334.00
DNA balance_sheet (quarterly, 2025-06-30) — Other Current Assets: 26208000.00
DNA balance_sheet (quarterly, 2025-06-30) — Other Equity Adjustments: 1653000.00
DNA income_statement (quarterly, 2025-06-30) — Other Gand A: 43279000.00
DNA income_statement (quarterly, 2025-06-30) — Other Income Expense: -4799000.00
DNA balance_sheet (quarterly, 2025-06-30) — Other Intangible Assets: 66152000.00
DNA balance_sheet (quarterly, 2025-06-30) — Other Investments: 16689000.00
DNA cash_flow (quarterly, 2025-06-30) — Other Non Cash Items: 13226000.00
DNA balance_sheet (quarterly, 2025-06-30) — Other Non Current Assets: 47020000.00
DNA balance_sheet (quarterly, 2025-06-30) — Other Non Current Liabilities: 17944000.00
DNA income_statement (quarterly, 2025-06-30) — Other Non Operating Income Expenses: -896000.00
DNA balance_sheet (quarterly, 2025-06-30) — Other Properties: 523688000.00
DNA balance_sheet (quarterly, 2025-06-30) — Other Short Term Investments: 270125000.00
DNA income_statement (quarterly, 2025-06-30) — Otherunder Preferred Stock Dividend: 0.00
DNA balance_sheet (quarterly, 2025-06-30) — Payables: 11202000.00
DNA balance_sheet (quarterly, 2025-06-30) — Payables And Accrued Expenses: 68433000.00
DNA balance_sheet (quarterly, 2025-06-30) — Preferred Stock: 0.00
DNA income_statement (quarterly, 2025-06-30) — Pretax Income: -60583000.00
DNA cash_flow (quarterly, 2025-06-30) — Proceeds From Stock Option Exercised: 0.00
DNA balance_sheet (quarterly, 2025-06-30) — Properties: 0.00
DNA cash_flow (quarterly, 2025-06-30) — Purchase Of Business: 0.00
DNA cash_flow (quarterly, 2025-06-30) — Purchase Of Investment: -128950000.00
DNA cash_flow (quarterly, 2025-06-30) — Purchase Of PPE: -38000.00
DNA balance_sheet (quarterly, 2025-06-30) — Receivables: 23126000.00
DNA income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 14822000.00
DNA income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 16337000.00
DNA cash_flow (quarterly, 2025-06-30) — Repayment Of Debt: -98000.00
DNA income_statement (quarterly, 2025-06-30) — Research And Development: 53370000.00
DNA income_statement (quarterly, 2025-06-30) — Restructuring And Mergern Acquisition: 3674000.00
DNA balance_sheet (quarterly, 2025-06-30) — Retained Earnings: -5988814000.00
DNA cash_flow (quarterly, 2025-06-30) — Sale Of Investment: 64958000.00
DNA income_statement (quarterly, 2025-06-30) — Selling General And Administration: 43279000.00
DNA balance_sheet (quarterly, 2025-06-30) — Share Issued: 55425334.00
DNA income_statement (quarterly, 2025-06-30) — Special Income Charges: -3674000.00
DNA cash_flow (quarterly, 2025-06-30) — Stock Based Compensation: 25292000.00
DNA balance_sheet (quarterly, 2025-06-30) — Stockholders Equity: 612952000.00
DNA balance_sheet (quarterly, 2025-06-30) — Tangible Book Value: 546800000.00
DNA income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: -18232.00
DNA income_statement (quarterly, 2025-06-30) — Tax Provision: -283000.00
DNA income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.00
DNA balance_sheet (quarterly, 2025-06-30) — Total Assets: 1231009000.00
DNA balance_sheet (quarterly, 2025-06-30) — Total Capitalization: 612952000.00
DNA balance_sheet (quarterly, 2025-06-30) — Total Debt: 428827000.00
DNA balance_sheet (quarterly, 2025-06-30) — Total Equity Gross Minority Interest: 612952000.00
DNA income_statement (quarterly, 2025-06-30) — Total Expenses: 111471000.00
DNA balance_sheet (quarterly, 2025-06-30) — Total Liabilities Net Minority Interest: 618057000.00
DNA balance_sheet (quarterly, 2025-06-30) — Total Non Current Assets: 707984000.00
DNA balance_sheet (quarterly, 2025-06-30) — Total Non Current Liabilities Net Minority Interest: 521337000.00
DNA income_statement (quarterly, 2025-06-30) — Total Operating Income As Reported: -65541000.00
DNA income_statement (quarterly, 2025-06-30) — Total Unusual Items: -3903000.00
DNA income_statement (quarterly, 2025-06-30) — Total Unusual Items Excluding Goodwill: -3903000.00
DNA balance_sheet (quarterly, 2025-06-30) — Working Capital: 426305000.00
DNA income_statement (quarterly, 2025-06-30) — Write Off: 0.00
DNA income_statement (quarterly, 2025-09-30) — +Operating Expense: 114307000.00
DNA income_statement (quarterly, 2025-09-30) — +Total Revenue: 38837000.00
DNA balance_sheet (quarterly, 2025-09-30) — Accounts Payable: 10704000.00
DNA balance_sheet (quarterly, 2025-09-30) — Accounts Receivable: 21430000.00
DNA balance_sheet (quarterly, 2025-09-30) — Accumulated Depreciation: -182075000.00
DNA balance_sheet (quarterly, 2025-09-30) — Additional Paid In Capital: 6627350000.00
DNA cash_flow (quarterly, 2025-09-30) — Asset Impairment Charge: 0.00
DNA balance_sheet (quarterly, 2025-09-30) — Available For Sale Securities: 13202000.00
DNA income_statement (quarterly, 2025-09-30) — Basic Average Shares: 55633718.00
DNA income_statement (quarterly, 2025-09-30) — Basic EPS: -1.45
DNA cash_flow (quarterly, 2025-09-30) — Beginning Cash Position: 251351000.00
DNA balance_sheet (quarterly, 2025-09-30) — Buildings And Improvements: 49760000.00
DNA balance_sheet (quarterly, 2025-09-30) — Capital Lease Obligations: 422870000.00
DNA balance_sheet (quarterly, 2025-09-30) — Capital Stock: 6000.00
DNA balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 111065000.00
DNA balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 461862000.00
DNA cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Financing Activities: 9938000.00
DNA cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Investing Activities: -72816000.00
DNA cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Operating Activities: -31606000.00
DNA cash_flow (quarterly, 2025-09-30) — Change In Other Current Assets: 87000.00
DNA cash_flow (quarterly, 2025-09-30) — Change In Other Current Liabilities: -7852000.00
DNA cash_flow (quarterly, 2025-09-30) — Change In Other Working Capital: -3533000.00
DNA cash_flow (quarterly, 2025-09-30) — Change In Payables And Accrued Expense: 22116000.00
DNA cash_flow (quarterly, 2025-09-30) — Change In Prepaid Assets: 2202000.00
DNA cash_flow (quarterly, 2025-09-30) — Change In Receivables: 757000.00
DNA cash_flow (quarterly, 2025-09-30) — Change In Working Capital: 13777000.00
DNA cash_flow (quarterly, 2025-09-30) — Changes In Account Receivables: 757000.00
DNA cash_flow (quarterly, 2025-09-30) — Changes In Cash: -94484000.00
DNA balance_sheet (quarterly, 2025-09-30) — Common Stock: 6000.00
DNA balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: 559783000.00
DNA balance_sheet (quarterly, 2025-09-30) — Construction In Progress: 0.00
DNA income_statement (quarterly, 2025-09-30) — Cost Of Revenue: 12802000.00
DNA balance_sheet (quarterly, 2025-09-30) — Current Accrued Expenses: 79341000.00
DNA balance_sheet (quarterly, 2025-09-30) — Current Assets: 506082000.00
DNA balance_sheet (quarterly, 2025-09-30) — Current Deferred Liabilities: 25236000.00
DNA balance_sheet (quarterly, 2025-09-30) — Current Deferred Revenue: 25236000.00
DNA balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 115281000.00
DNA cash_flow (quarterly, 2025-09-30) — Depreciation Amortization Depletion: 14168000.00
DNA cash_flow (quarterly, 2025-09-30) — Depreciation And Amortization: 14168000.00
DNA income_statement (quarterly, 2025-09-30) — Diluted Average Shares: 55633718.00
DNA income_statement (quarterly, 2025-09-30) — Diluted EPS: -1.45
DNA income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: -80755000.00
DNA balance_sheet (quarterly, 2025-09-30) — Duefrom Related Parties Current: 929000.00
DNA income_statement (quarterly, 2025-09-30) — EBIT: -88272000.00
DNA income_statement (quarterly, 2025-09-30) — EBITDA: -74104000.00
DNA cash_flow (quarterly, 2025-09-30) — Effect Of Exchange Rate Changes: 93000.00
DNA cash_flow (quarterly, 2025-09-30) — End Cash Position: 156960000.00
DNA balance_sheet (quarterly, 2025-09-30) — Financial Assets: 284000.00
DNA cash_flow (quarterly, 2025-09-30) — Financing Cash Flow: 9938000.00
DNA cash_flow (quarterly, 2025-09-30) — Free Cash Flow: -31606000.00
DNA income_statement (quarterly, 2025-09-30) — Gain On Sale Of Business: 0.00
DNA income_statement (quarterly, 2025-09-30) — Gain On Sale Of Security: 3684000.00
DNA balance_sheet (quarterly, 2025-09-30) — Gains Losses Not Affecting Retained Earnings: 1996000.00
DNA income_statement (quarterly, 2025-09-30) — General And Administrative Expense: 44954000.00